NCT04456361View on ClinicalTrials.gov

Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 16, 2020

Primary Completion Date

February 15, 2025

Study Completion Date

November 15, 2025

Conditions
ARDS, HumanCovid-19
Interventions
BIOLOGICAL

Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords

Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.

Trial Locations (1)

22100

Instituto de Medicina Regenerativa, Tijuana

All Listed Sponsors
lead

Instituto de Medicina Regenerativa

INDUSTRY